News

The makers of leronlimab (PRO 140) have filed the non-clinical portion of the drug’s Biologics License Application as a combination therapy for HIV with the FDA.

A communitywide HIV prevention package including in-home testing and antiretroviral therapy reduces new infections, according to a study from the HIV Prevention Trials Network.

Sulopenem, which is a novel penem anti-infective compound with both IV and oral formulations, has been granted QIDP status for 4 new indications, totaling 7 in total.

A study presented at CROI 2019 found that interventions to support PrEP persistence for younger black MSM will be necessary in order for the full effectiveness of PrEP to be achieved.

On-demand pre-exposure prophylaxis with TDF/FTC is not associated with a clinically relevant change in kidney function the way daily PrEP use is, investigators in France found.

CROI 2019 was held March 4-7, 2018, in Seattle, Washington. The conference featured results of new studies on a variety of HIV topics as well as advancements being made in the field. Here are 5 key takeaways from the meeting.

A new protocol avoids spinal taps and antibiotics in the quest for evaluating febrile infants.

Although the cause of childhood-onset type 1 diabetes remains unknown, a new study links a precursor of the condition to an abundance of certain viruses in the gut.

Ceftazidime and avibactam is now approved for the treatment of pediatric patients between 3 months and 17 years with cUTI and cIAI.

Clostridium difficile rates in stem cell transplant patients are approximately 9 times greater than in hospitalized patients, with rates about twice as high in allogeneic vs autologous transplants.

We’ve rounded up a list of important US Food and Drug Administration (FDA) and US Department of Agriculture (USDA) recalls from this past week.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

A multistate outbreak of Salmonella Schwarzengrund has been attributed to consumption of ground turkey.

Although 30% of adults with XDR TB are successfully cured or complete treatment, a new study has found that children have far more favorable outcomes and lower mortality rates.

From the London Patient to the DISCOVER trial and everything in between, HIV experts provide their biggest takeaways from CROI 2019, in the second part of our highlight reel.

A London study shows that men infected with HIV are acquiring HCV at much lower levels than before.

Post-discharge decolonization education and bioburden reduction could be critical to reducing MRSA infections.

Hospitals that try to discourage the use of fluoroquinolones succeed at lowering prescriptions for patients admitted to the hospital, but many of those patients still leave with prescriptions for fluoroquinolones at discharge.

From the London Patient to the DISCOVER trial and everything in between, HIV experts provide their biggest takeaways from CROI 2019.

Responses to 10 university-based outbreaks of meningococcal disease caused by serogroup B underscored the importance of MenB vaccination coverage to protect students.

The first study to evaluate the cost-effectiveness of hepatitis C virus (HCV) screening among pregnant women in the US in the era of direct-acting antiviral (DAA) treatment demonstrates that it would be "highly" cost effective, even in states with low HCV prevalence.

Countries around the world begin to respond to measles outbreaks, with Italy taking the step of keeping unvaccinated kids home from school.

Kristine Erlandson, MD, MS, shares her findings on the connection between obesity and neurocognitive decline in persons with HIV.

Short-term investments in pre-exposure prophylaxis (PrEP) are predicted to result in long-term cost-savings and promote significant health benefits following its distribution in Germany, according to a new modelling study in Eurosurveillance.

In a symposium at CROI 2019, Jean-Michele Molina, MD, presented on PrEP failures, highlighting elements of diagnosis, resistance and treatment.

Staph infections aren't going away and now a new report says we're not doing as well as we think.

Monica Gandhi, MD, MPH, discusses antiretroviral options and and treatment decisions for women of reproductive potential.

In a symposium at CROI 2019, Laura Waters, MD, FRCP, presented on the developments of 2-drug regimens for HIV treatments, as well as the questions that remain unanswered.